Survival Study in Heart Failure) (1) . Although all patients were in NYHA functional class II at entry, when categorized into low-, medium-, and high-risk groups using a predictive score, the rate of the primary endpoint (cardiovascular death or HF hospitalization) ranged from 7.6 to 39.4 per 100 person-years in the placebo-treated patients (the rate in the medium-risk group was 19.0 per 100 person-years) (2) .
Most patients in the PARADIGM-HF (Prospective
Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial also had mild symptoms (5% were in NYHA functional class I and 70% in class II), although 24% and 0.7% were in NYHA functional classes III and IV, respectively, at randomization (3). We therefore calculated the baseline risk of patients in PARADIGM-HF using the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) risk score, which was derived and validated in patients with a broad spectrum of symptoms and functional limitations (4) . We also analyzed risk using the EMPHASIS-HF score in PARADIGM-HF patients in NYHA functional classes I and II only (2) . Additionally, we examined the effect of the angiotensin receptor neprilysin inhibitor LCZ696 compared with enalapril, according to baseline risk calculated using these scores.
METHODS
The study design, patient characteristics, and key results of the PARADIGM-HF trial have been described in detail (3, (5) (6) (7) . The ethics committee of each of the 1,043 participating institutions (in 47 countries) approved the protocol, and all patients gave written, informed consent.
PATIENTS AND PROCEDURES
Patients had NYHA functional class II through IV symptoms, LVEF #40% (changed to #35% by amendment), and plasma B-type natriuretic peptide (BNP) levels $150 pg/ml (or N-terminal pro-BNP levels $600 pg/ml). Patients who had been hospitalized for HF within 12 months were eligible for enrollment with lower natriuretic peptide concentrations (BNP $100 pg/ml or N-terminal pro-BNP $400 pg/ml). Patients also were required to be taking angiotensin-converting enzyme inhibitors RISK SCORES. The baseline risk for each patient in PARADIGM-HF was calculated using the MAGGIC score, the derivation and validation of which have been published (4, 8 The interaction between treatment and risk score was conducted with the risk score as a continuous variable. Pre-specified adverse events according to risk score category were also examined. Figure 1A shows the distribution of MAGGIC risk scores in PARADIGM-HF.
The median score was 20 points (IQR: 16 to 24 points; range: 4 to 40 points). OUTCOMES. When examined as a continuous variable, each 1-point increase in score was associated with a 6% (95% confidence interval: 5% to 7%)
higher risk for the primary composite outcome of cardiovascular death or HF hospitalization (p < 0.001) ( Figure 1A ).
The unadjusted incidence of the primary outcome according to baseline risk category and randomized treatment is shown in Table 2 and the Central Illustration (as a rate per 100 patient-years of Values are mean AE SD, n (%), or median (interquartile range).
BMI ¼ body mass index; BNP ¼ B-type natriuretic peptide; DBP ¼ diastolic blood pressure; eGFR ¼ estimated glomerular filtration rate; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; MAGGIC ¼ Meta-Analysis Global Group in Chronic Heart Failure; NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure. Generally, patients with AF had higher absolute rates 
CV death or HF hospitalization Simpson et al. After categorizing patients into quintiles on the basis of the Meta-Analysis Global Group in Chronic Heart Failure risk score, the rate per 100 patient-years of follow-up was determined for (A) the primary composite endpoint, (B) cardiovascular (CV) death, (C) heart failure (HF) hospitalization, and (D) all-cause mortality according to baseline risk category and randomized treatment. The incidence of all endpoints increased incrementally with increasing risk score. The effect of LCZ696 compared with enalapril was consistent across the range of risk scores examined as a categorical variable for all endpoints.
MAGGIC ¼ Meta-Analysis Global Group in Chronic Heart Failure. Moreover, the benefit of LCZ696 over enalapril was consistent across risk categories in both rhythm subgroups (Online Tables 3 to 6 ).
Regionally, the rate of death tended to be lower and that of HF hospitalization higher in Europe and
North America compared with the rest of the world, but the rate of the primary composite outcome did not vary markedly between regions. Event rates increased with increasing risk score in each region, and the benefit of LCZ696 over enalapril was consistent across risk categories in both regions (Online Tables 7 to 10 ).
ADVERSE EVENTS. Among pre-specified safety outcomes in PARADIGM-HF by MAGGIC risk score category ( were men. Figure 1B shows the distribution of EMPHASIS-HF risk scores in this subset of patients in PARADIGM-HF. The median score was 5 points (IQR: 4 to 6 points; range: 0 to 12 points). Table 4 shows the number and proportion of patients in the different EMPHASIS-HF risk-score categories analyzed.
The differences between those with lower and higher EMPHASIS-HF risk scores exactly mirrored those reported for the MAGGIC risk score. Similar to the (Table 5) . Likewise, the effect of LCZ696 compared with enalapril was consistent across the range of risk scores examined as a categorical (Figure 2 ) or continuous ( Figure 1B) variable, with the greatest absolute benefit in those at highest risk. Values are mean AE SD, n (%), or median (interquartile range).
EMPHASIS-HF ¼ Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure; other abbreviation as in Table 1 . 
CV death or HF hospitalization *With NYHA functional class I or II heart failure. †Rate per 100 patient-years. Tables 1 and 2 .
Abbreviations as in
Simpson et al. Limitations inherent to secondary analyses must also be considered when interpreting these results; in particular, the analyses were not powered for this purpose. The MAGGIC score was developed to estimate the risk for all-cause mortality, whereas we have used this score to stratify patients in relation to risk for several other outcomes. However, as shown earlier, the MAGGIC score seemed to discriminate risk for these other outcomes. Moreover, we used an alternative score, the EMPHASIS-HF risk score, which 
